Chengdu Yuanhengkang Biotech

Chengdu Yuanhengkang Biotech is a clinical-stage biopharmaceutical company based in Chengdu, China, focused on the discovery and development of innovative small molecule therapeutics. The company utilizes its proprietary structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) platforms to target metabolic diseases, immunology, and oncology. Its lead candidate, YHK-1102, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the company is advancing YHK-1301, a potent URAT1 inhibitor for gout and hyperuricemia, which has entered clinical evaluation. Yuanhengkang Biotech aims to address significant unmet medical needs by developing best-in-class oral medications with improved safety and efficacy profiles. The company is supported by prominent venture capital firms and is situated within the Chengdu Tianfu International Bio-Town.